Disposition of metabolically radiolabeled CE9.1 - A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 1032-1037

  Davis, Charles B ^a,b   Garver, Eric M ^a   Kwok, Deborah C ^a   Urbanski, James J ^a  

^a SmithKline Beecham Pharmaceuticals   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OKT 4; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHO CELL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; AREA UNDER CURVE; HUMANS; LEUCINE; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SPLEEN; TISSUE DISTRIBUTION; TRITIUM;

ANIMALIA; MUS MUSCULUS; PAN TROGLODYTES;

EID: 0029790348     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. R. Newman, J. Alberts, D. Anderson, K. Carner, C. Heard, F. Norton, R. Raab, M. Reff, S. Shuey, and N. Hanna: "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque-human chimeric antibody against human CD4. Biotechnology 10, 1455-1460 (1992).
2. N. Killeen, S. Sawada, and D. R. Littman: Regulated expression of human CD4 rescues helper cell development in mice lacking expression of endogenous CD4. EMBO J. 12, 1547-1553 (1993).
3. C. B. Davis, K. E. Boyle, J. J. Urbanski, R. T. Paradysz, and K.-L. L. Fong: Disposition of metabolically labeled recombinant soluble CD4 (sT4) in male Sprague-Dawley rats following intravenous and subcutaneous administration. Drug Metab. Dispos. 20, 695-705 (1992).
4. B. Davies and T. Morris: Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
5. R. G. Hamilton and S. L. Morrison: Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched deleted and point-mutated chimeric antibodies. J. Immunol. Methods 158, 107-122 (1993).
6. C. B. Davis, T. W. Hepburn, J. J. Urbanski, D. C. Kwok, T. K. Hart, D. J. Herzyk, S. G. Demuth, M. Leland, and G. R. Rhodes: Pre-clinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab. Dispos. 23, 1028-1036 (1995).
7. A. H. Schinkel, J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. J. te Riele, A. J. M. Berns, and P. Borst: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
8. S. D. Yoo, J. W. Holladay, T. K. Fincher, H. Baumann, and M. J. Dewey: Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther. 276, 918-922 (1996).
9. T. A. Waldmann and W. Strober: Metabolism of immunoglobulins. Progr. Allergy 13, 1-110 (1969).